Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Asthma Model of Care due this summer

By Mindo - 07th Feb 2018 | 35 views

According to the National Clinical Lead of the HSE’s Asthma Programme, Prof Pat Manning, the long-awaited model of care is still being worked on but should be ready for publication sometime in the summer.

Speaking to the <strong><em>Medical Independent</em></strong> (<strong><em>MI</em></strong>), the consultant respiratory physician outlined that a high-level implementation plan would be devised when the model of care is complete.

The development of an implementation plan is now a requirement for all new HSE model of care plans, it is understood.

“We hope to have the model of care completed by mid-year and the high-level implementation plan developed after that,” Prof Manning noted.

He added that the model of care, developed initially in 2010/2011, is currently being updated in line with the integrated care programmes. A section on paediatric care is also being updated, along with data on asthma epidemiology.

The publication of the model of care was previously put on hold following the start of  GP contract negotiations.

Meanwhile, a medication for the treatment of severe asthma has been cleared for reimbursement by the HSE. 

The HSE Drugs Group agreed last year that mepolizumab, initially refused for reimbursement, would now be reimbursed after the commercial offering satisfied “conventional, cost effectiveness thresholds”, according to information released under the Freedom of Information Act.

Prior to this decision, mepolizumab was reviewed by the National Centre for Pharmacoeconomics (NCPE) and deemed too costly for reimbursement.

It is understood that mepolizumab could help reduce severe asthma attacks in around 500 Irish patients. The drug is usually injected every four weeks and claims to reduce severe asthma attacks, hospital admissions and the use of oral steroids.

Leave a Reply

Latest Issue
The Medical Independent 30th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read